Fig. 5From: SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemiaSLC22A3 expression in the surveillance of AML. A SLC22A3 expression in different clinical stages (new diagnosis, complete remission, and relapsed time) of AML patients. B Dynamic change of SLC22A3 expression in eight patients during different clinical stagesBack to article page